Switch theme
Sign up to access all valuation multiples
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
2017
142
LTM Revenue $52.4M
LTM EBITDA -$34.8M
$240M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Aquestive Therapeutics has a last 12-month revenue (LTM) of $52.4M and a last 12-month EBITDA of -$34.8M.
In the most recent fiscal year, Aquestive Therapeutics achieved revenue of $57.6M and an EBITDA of -$26.6M.
Aquestive Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Aquestive Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $52.4M | XXX | $57.6M | XXX | XXX | XXX |
| Gross Profit | $35.2M | XXX | $39.7M | XXX | XXX | XXX |
| Gross Margin | 67% | XXX | 69% | XXX | XXX | XXX |
| EBITDA | -$34.8M | XXX | -$26.6M | XXX | XXX | XXX |
| EBITDA Margin | -66% | XXX | -46% | XXX | XXX | XXX |
| EBIT | -$40.6M | XXX | -$30.8M | XXX | XXX | XXX |
| EBIT Margin | -78% | XXX | -53% | XXX | XXX | XXX |
| Net Profit | -$54.1M | XXX | -$44.1M | XXX | XXX | XXX |
| Net Margin | -103% | XXX | -77% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Aquestive Therapeutics's stock price is $3.
Aquestive Therapeutics has current market cap of $270M, and EV of $240M.
See Aquestive Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $240M | $270M | XXX | XXX | XXX | XXX | $-0.59 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Aquestive Therapeutics has market cap of $270M and EV of $240M.
Aquestive Therapeutics's trades at 4.2x EV/Revenue multiple, and -9.0x EV/EBITDA.
Equity research analysts estimate Aquestive Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Aquestive Therapeutics has a P/E ratio of -5.0x.
See valuation multiples for Aquestive Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $270M | XXX | $270M | XXX | XXX | XXX |
| EV (current) | $240M | XXX | $240M | XXX | XXX | XXX |
| EV/Revenue | 4.6x | XXX | 4.2x | XXX | XXX | XXX |
| EV/EBITDA | -6.9x | XXX | -9.0x | XXX | XXX | XXX |
| EV/EBIT | -5.9x | XXX | -7.8x | XXX | XXX | XXX |
| EV/Gross Profit | 6.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.0x | XXX | -6.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -6.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAquestive Therapeutics's last 12 month revenue growth is 2%
Aquestive Therapeutics's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.5M for the same period.
Aquestive Therapeutics's rule of 40 is 4% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Aquestive Therapeutics's rule of X is -62% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Aquestive Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | -66% | XXX | -46% | XXX | XXX | XXX |
| EBITDA Growth | 23% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 4% | XXX | -45% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -62% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 35% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 122% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aquestive Therapeutics acquired XXX companies to date.
Last acquisition by Aquestive Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Aquestive Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Aquestive Therapeutics founded? | Aquestive Therapeutics was founded in 2017. |
| Where is Aquestive Therapeutics headquartered? | Aquestive Therapeutics is headquartered in United States of America. |
| How many employees does Aquestive Therapeutics have? | As of today, Aquestive Therapeutics has 142 employees. |
| Who is the CEO of Aquestive Therapeutics? | Aquestive Therapeutics's CEO is Mr. Daniel Barber. |
| Is Aquestive Therapeutics publicy listed? | Yes, Aquestive Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Aquestive Therapeutics? | Aquestive Therapeutics trades under AQST ticker. |
| When did Aquestive Therapeutics go public? | Aquestive Therapeutics went public in 2018. |
| Who are competitors of Aquestive Therapeutics? | Similar companies to Aquestive Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Aquestive Therapeutics? | Aquestive Therapeutics's current market cap is $270M |
| What is the current revenue of Aquestive Therapeutics? | Aquestive Therapeutics's last 12 months revenue is $52.4M. |
| What is the current revenue growth of Aquestive Therapeutics? | Aquestive Therapeutics revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Aquestive Therapeutics? | Current revenue multiple of Aquestive Therapeutics is 4.6x. |
| Is Aquestive Therapeutics profitable? | Yes, Aquestive Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Aquestive Therapeutics? | Aquestive Therapeutics's last 12 months EBITDA is -$34.8M. |
| What is Aquestive Therapeutics's EBITDA margin? | Aquestive Therapeutics's last 12 months EBITDA margin is -66%. |
| What is the current EV/EBITDA multiple of Aquestive Therapeutics? | Current EBITDA multiple of Aquestive Therapeutics is -6.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
